ACHV

In November 2025, the company reported Q3 earnings, which was followed by a share price decline. In March 2026, Achieve Life Sciences reported earnings, leading to a significant share price decrease due to FDA concerns about cytisinicline manufacturing. In April 2026, the stock increased, and the company announced a private placement for up to $354 million and appointed a new CEO. In May 2026, the company is expected to announce its next earnings and hosted a conference call to discuss its first-quarter financial results; the share price increased significantly from the previous year.